What does Semax actually do? Evidence from Russian trials

Last updated 2026-07-24

What is Semax and where does the evidence come from?

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) engineered from the first four amino acids of adrenocorticotropic hormone (ACTH) plus a stabilizing Pro-Gly-Pro tripeptide tail ^[1]. It was developed in Russia in the 1980s and has been used clinically there for decades, primarily as an intranasal spray for acute ischemic stroke, cognitive impairment, and attention disorders ^[2]. The evidence base is unusual. Semax has never completed FDA-review clinical trials or been approved for sale in the United States. The bulk of the literature is Russian-language, published in Russian journals, and has not been independently replicated in large Western trials. That doesn't mean the research is worthless. It means you're reading preclinical animal models, small open-label human studies, and mechanistic genomic work that meets Russian regulatory standards but hasn't cleared the Western evidence bar ^[3]. The peptide does not appear on the FDA's 503A or 503B bulk drug lists, so U.S. compounding pharmacies cannot legally prepare it for patients under current federal rules ^[4][5]. It circulates in the nootropics research-peptide market, typically sourced from manufacturers overseas. If you're weighing whether to use it, you're doing so with animal data, a handful of Russian stroke trials, and mechanistic plausibility, not a Cochrane review.

How does Semax interact with brain-derived neurotrophic factor?

One of the most consistently replicated findings is that Semax increases levels of brain-derived neurotrophic factor (BDNF) protein in specific brain regions ^[6]. In one rodent study, intranasal administration at 50 micrograms per rat led to selective BDNF elevation in the hippocampus and frontal cortex, regions tied to memory and executive function, with no change in the striatum ^[6]. The peptide also upregulates the transcription of BDNF's gene and its receptor TrkB after cerebral ischemia in animal models ^[7]. BDNF is the brain's most abundant neurotrophin. It drives synaptic plasticity, neuronal survival, and long-term potentiation, the cellular correlate of learning. Higher BDNF is associated with better cognitive performance and resilience to neurodegenerative insults. The catch: BDNF levels fluctuate with exercise, sleep, diet, and stress, and we have no human studies measuring whether Semax raises BDNF in people or whether any such increase translates to measurable cognitive gain. The binding mechanism is unclear. Semax doesn't act through classical ACTH receptors (melanocortin receptors), and its BDNF effect appears to be indirect, possibly mediated by monoaminergic or cholinergic pathways ^[6]. It's a pharmacological effect, not a supplement-style replenishment.

What neurotransmitter systems does Semax affect?

Semax modulates dopamine and serotonin metabolism in the brain ^[8]. In rodent striatum and hypothalamus, it increases dopamine turnover (the ratio of metabolites to parent molecule), suggesting enhanced dopaminergic activity without necessarily raising baseline dopamine levels ^[8]. It also raises serotonin turnover in the hypothalamus and lowers it in some cortical regions, hinting at region-specific serotonergic effects ^[8]. Recent work ties Semax to the μ-opioid receptor (encoded by the gene Oprm1). In female mice with spinal cord injury, Semax promoted deubiquitination of Oprm1, stabilizing the receptor and improving functional recovery ^[9]. The authors propose this mechanism contributes to its analgesic and neuroprotective effects, though sex-specific receptor dynamics complicate generalization ^[9]. Semax also interacts with GABA receptors. One study found that it potentiates GABA_A receptor signaling in certain brain regions, which could explain reported anxiolytic effects ^[10]. These are not simple on-off switches. Dopamine, serotonin, opioids, and GABA are all subject to feedback loops, receptor desensitization, and regional heterogeneity, so a peptide that shifts turnover rates in one region under one condition may do nothing, or the opposite, in another.

What does Semax do to gene expression after stroke?

The most detailed mechanistic picture comes from genome-wide transcriptional studies in rats subjected to focal cerebral ischemia and then treated with Semax. One 2014 study found that Semax (administered intranasally at 50 micrograms per kilogram) altered the expression of hundreds of genes related to immune response, vascular remodeling, and cell survival ^[11]. Specifically, it downregulated inflammatory cytokine genes and upregulated genes involved in angiogenesis and neurogenesis ^[11]. A 2024 follow-up using next-generation sequencing confirmed that Semax, given one day after experimental stroke, partially normalized the expression of genes disrupted by ischemia ^[12]. The peptide's effects were most pronounced in the penumbra, the zone of threatened but salvageable tissue surrounding the infarct core ^[13]. Genes tied to oxidative stress, apoptosis, and immune infiltration were the primary targets ^[13]. A 2020 proteomic study measured actual protein levels rather than mRNA and found that Semax shifted the brain's protein expression profile toward neuroprotection, with increases in heat shock proteins, antioxidant enzymes, and synaptic scaffold proteins ^[14]. Another group reported that Semax modulates transthyretin, a transport protein that may regulate amyloid-beta clearance, suggesting a possible role in Alzheimer's pathology ^[15]. These are animal studies. The doses are calibrated to rodent physiology, the timing is controlled, and the endpoints are molecular. We don't know which of these genomic changes occur in human brains, at what doses, or whether they matter clinically.

Does Semax work in human stroke patients?

Russian clinicians have used Semax as an add-on therapy for acute ischemic stroke since the 1990s. A 2018 review in the Russian journal Zhurnal nevrologii i psikhiatrii summarized efficacy data across multiple trials, reporting that Semax improved neurological outcomes when started within 6 to 12 hours of stroke onset and continued for 5 to 10 days ^[16]. The typical protocol was intranasal administration at 12 to 18 milligrams per day, divided into multiple doses. The evidence quality is poor by Western standards. Most trials were open-label, lacked sham controls, used non-standardized outcome measures, and enrolled small cohorts. Publication in Russian-language specialty journals means limited external peer scrutiny and low visibility to the international stroke community. No Phase III randomized controlled trial has been published in English in a high-impact neurology journal. That said, the consistency across studies is notable. Multiple independent groups in different Russian institutions reported faster neurological recovery, reduced infarct volume on imaging, and better functional status at 90 days when Semax was added to standard care ^[16]. If we had equivalent Western data, it would be considered preliminary but hypothesis-generating. As it stands, you have to decide whether decades of Russian clinical experience count for something or count for nothing.

What are the cognitive effects in healthy people?

We have almost no placebo-controlled data on Semax in cognitively normal humans. The peptide's nootropic reputation rests on animal studies showing improved learning and memory, anecdotal reports from the biohacking community, and extrapolation from stroke recovery data. One small study tested Semax's effects on the default mode network (DMN), a set of brain regions active during rest and implicated in self-referential thought and mind-wandering ^[17]. Using functional MRI, researchers found that a single intranasal dose of Semax (100 micrograms per kilogram) altered DMN connectivity in healthy volunteers, with increased coupling between the posterior cingulate cortex and frontal regions ^[17]. The authors suggest this might correspond to improved attentional control, but they didn't measure actual cognitive performance or follow subjects beyond one session. Another study in rats showed that Semax administered intranasally, subcutaneously, or intraperitoneally all produced dose-dependent improvements in spatial memory tasks, with intranasal dosing being the most efficient ^[18]. That's useful for understanding delivery routes but tells you nothing about whether a human taking 600 micrograms intranasally before an exam will remember more facts. The peptide has been explored as a potential treatment for depression. A 2008 case series in CNS Spectrums reported that Semax, given intranasally at 3 milligrams per day for 14 days, reduced depression scores in a small cohort of patients with major depressive disorder ^[19]. The study was unblinded, had no placebo arm, and has not been replicated. If you're considering Semax for cognitive enhancement, you're extrapolating from rodent behavior, stroke recovery, and receptor pharmacology. That's not irrational, but it's not evidence-based medicine either.

How does Semax affect amyloid-beta and Alzheimer's models?

Semax has been tested in rodent models of Alzheimer's disease, where it shows some ability to reduce amyloid-beta (Aβ) aggregation and correct behavioral deficits ^[20]. One 2022 study found that Semax interfered with copper-induced Aβ aggregation in artificial membrane models, suggesting it might modulate the metal-catalyzed misfolding that drives plaque formation ^[21]. The effect was dose-dependent and related to the peptide's N-terminal acetylation, which enhances its affinity for copper and zinc ions ^[22]. In a 2025 study using rats injected with Aβ(1-42) peptide to simulate Alzheimer's pathology, Semax and one of its metabolites partially reversed memory deficits and reduced oxidative stress markers in the hippocampus ^[20]. The treated animals performed better in spatial learning tasks and showed fewer signs of neuronal degeneration on histology ^[20]. The literature on bioactive peptides in neurodegeneration is littered with compounds that look promising in cell culture and animal models but fail in humans ^[23]. Semax has never been tested in a clinical trial of Alzheimer's patients, so everything here is preclinical speculation. The metal-binding angle is interesting mechanistically, but it's not a reason to use Semax off-label for dementia.

What is the pharmacokinetics and stability of Semax?

Semax is administered intranasally because it's a peptide and would be digested if swallowed. Intranasal delivery allows some direct nose-to-brain transport via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier ^[18]. Peak effects in rodent studies occur 15 to 60 minutes post-dose, and behavioral effects last 4 to 8 hours ^[18]. The peptide is rapidly degraded by proteases. Its half-life in serum is short, on the order of minutes, which is why clinical protocols use multiple daily doses. The Pro-Gly-Pro tail at the C-terminus was engineered specifically to slow enzymatic cleavage and extend duration of action ^[1]. Even so, Semax doesn't accumulate, and there's no evidence of long-lasting changes in receptor density or gene expression after cessation in short-term studies. N-acetylation of the N-terminus (as in N-acetyl-semax-amidate, a related analog) further increases stability and alters pharmacodynamics ^[22]. The acetylated version has a longer half-life, different metal-binding properties, and may have distinct cognitive effects, though head-to-head human comparisons don't exist ^[22]. If you're sourcing Semax from a research supplier, the formulation matters.

Where can you actually get Semax in the United States?

Semax is not FDA-approved and does not appear on the agency's bulk drug substances lists for compounding under 21 CFR 216.23 or 21 CFR 216.24 ^[4][5]. That means licensed U.S. compounding pharmacies operating under 21 U.S.C. 353a cannot legally compound it ^[24]. Any U.S. pharmacy selling Semax is doing so outside the regulatory framework, risking enforcement action. The peptide is available from research chemical suppliers, typically as a lyophilized powder or pre-mixed nasal solution. These vendors operate in a legal gray zone: selling peptides "not for human consumption" but tacitly understood to be used by individuals for self-experimentation. Quality is variable. You have no assurance of purity, sterility, or accurate dosing unless you pay for third-party testing, which most buyers don't. Semax Labs offers Semax nasal spray through a provider-reviewed pathway, working with licensed pharmacy partners where legally permissible. That model provides some oversight, though it still operates at the edge of FDA tolerance and may not be available in all states. If your priority is legal clarity and product traceability, the current U.S. market doesn't offer much. Importing Semax for personal use from overseas is also a gray area. U.S. Customs and Border Protection can seize unapproved drugs, and the FDA can issue warning letters, but enforcement against individuals ordering small quantities of research peptides is sporadic ^[25]. You're taking a legal risk alongside the pharmacological one.

What's the dosing for cognitive and neuroprotective use?

Russian clinical protocols for stroke use 12 to 18 milligrams per day, divided into two to three intranasal doses, for 5 to 10 days ^[16]. For cognitive enhancement or chronic use, anecdotal reports and sparse clinical mentions suggest 300 to 1,000 micrograms per dose, once or twice daily. There is no dose-finding study in healthy humans, so everything here is guesswork informed by rodent allometry and stroke data. Rodent studies often use 50 micrograms per kilogram, which scales to roughly 600 micrograms for a 70-kilogram human using simple body surface area conversion ^[18]. That's the dose range where effects on BDNF, dopamine turnover, and gene expression have been documented in animals ^[6][8]. Whether it's the right dose for cognition, mood, or neuroprotection in people is unknown. Intranasal bioavailability is low, probably in the range of 5 to 20 percent, with most of the dose draining into the gastrointestinal tract where it's degraded ^[18]. That's why clinical doses are measured in milligrams while effective brain concentrations are likely nanomolar. More on dosing in how many mg of Semax a day. If you're using Semax experimentally, start low. A single 300-microgram dose (0.3 mg) is unlikely to cause acute harm and lets you assess subjective response before escalating. Some users report stimulant-like effects (increased alertness, motivation) that suggest dopaminergic activity, while others notice nothing ^[26]. There is no standard titration schedule.

What are the risks and side effects?

Reported side effects in Russian trials were mild and infrequent: nasal irritation, transient headache, and occasional restlessness ^[16]. No serious adverse events were attributed to Semax in the published stroke literature, though reporting standards in those trials were not rigorous by modern Western criteria. Peptides carry inherent immunogenicity risk. Foreign amino acid sequences can, in theory, provoke antibody formation, leading to allergic reactions or loss of efficacy over time. This has not been documented with Semax in the available literature, but chronic use data are sparse. The bigger risk is product quality. If you're buying from a research supplier, you could be dosing degraded peptide, bacterial endotoxin, or the wrong compound entirely. Nasal administration bypasses some hepatic first-pass metabolism, meaning contaminants go straight to systemic circulation. There have been no published case reports of Semax toxicity in humans, but absence of reports is not evidence of safety when most use is off-book. More detail on the adverse event profile in Semax side effects. If you have a history of seizures, psychiatric illness, or are on medications that affect monoamine neurotransmitters, adding an unapproved peptide with dopaminergic and serotonergic activity is not a good idea without medical supervision.

Frequently asked questions

Is Semax FDA-approved?

No. Semax has never completed FDA review and is not approved for any indication in the United States. It does not appear on the FDA's bulk drug lists for compounding, so U.S. pharmacies cannot legally compound it under federal pharmacy law.

Does Semax actually increase BDNF in humans?

We don't know. Rodent studies show increased BDNF protein in the hippocampus and frontal cortex after intranasal Semax, but no published trial has measured BDNF levels in human cerebrospinal fluid or serum before and after Semax dosing.

How is Semax different from regular ACTH?

Semax is a synthetic analog of the first four amino acids of ACTH (Met-Glu-His-Phe) with a Pro-Gly-Pro tail added for stability. It does not activate melanocortin receptors or stimulate cortisol release like full-length ACTH. Its effects are on neurotransmitter systems and gene expression, not the adrenal axis.

Can I take Semax orally?

No. Semax is a peptide and would be digested by proteases in the stomach and intestine before reaching systemic circulation. Intranasal administration is the standard route. Injectable forms exist but are not common in research markets.

Is the Russian research on Semax reliable?

The studies are real and published in peer-reviewed Russian journals, but they don't meet Western standards for clinical trial design: most lack placebo controls, use small samples, and report outcomes that aren't standardized internationally. The animal mechanistic work is solid; the human efficacy data are preliminary.

What's the difference between Semax and N-acetyl-semax-amidate?

N-acetyl-semax-amidate has an acetyl group on the N-terminus and an amide cap on the C-terminus, making it more resistant to enzymatic degradation. It has a longer half-life and different metal-binding properties. We have even less human data on the acetylated version. More in Semax vs N-acetyl-semax-amidate.

How long does Semax stay in your system?

Semax has a serum half-life of minutes. Behavioral effects in rodents last 4 to 8 hours after a single intranasal dose, suggesting that its downstream effects on neurotransmitter turnover and gene transcription persist longer than the peptide itself.

Can Semax help with ADHD?

There are no controlled trials in ADHD patients. Semax increases dopamine turnover in the striatum and modulates frontal cortex connectivity, mechanisms relevant to attention, but anecdotal reports and one open-label Russian study are not evidence of efficacy for ADHD.

Is Semax legal to buy in the U.S.?

Semax is not a scheduled controlled substance, so possession is not illegal. But it's not approved for human use, so sellers market it as a research chemical. Importing it for personal use is a gray area that carries risk of customs seizure.

Does Semax cause tolerance or dependence?

There is no published evidence of tolerance, withdrawal, or dependence in the animal or human literature. Russian stroke trials used it for 5 to 10 days, and anecdotal long-term users report no obvious tachyphylaxis, but systematic studies of chronic use don't exist.

Should I take Semax for stroke recovery?

That is a medical decision. If you've had a stroke, you're under the care of a neurologist who should know about any off-label treatments you're considering. The Russian data suggest potential benefit when started acutely, but no Western stroke guidelines include Semax, and your doctor may not be familiar with it.

Where do most people buy Semax?

Research chemical suppliers and overseas peptide vendors. Quality and legality are both uncertain. Where to buy Semax (r/nootropics context) covers the landscape. Some U.S. providers offer it through provider-reviewed pathways in partnership with compounding pharmacies, operating in a regulatory gray zone.

Can Semax prevent Alzheimer's disease?

No evidence supports that. Rodent models show Semax reduces amyloid-beta aggregation and improves memory in Aβ-injected rats, but animal models of Alzheimer's have a terrible track record of predicting human efficacy. It has never been tested in people with dementia.

Is subcutaneous injection better than intranasal for Semax?

Intranasal and subcutaneous routes both work in rodents, with intranasal being slightly more efficient for cognitive effects, possibly due to direct nose-to-brain transport. Injectable Semax is less common in research markets and raises sterility and infection risk if you're doing it yourself. More on routes in Semax injection.

Sources

1. Pharmacological Aspects of Neuro-Immune Interactions (Current pharmaceutical design, 2018): Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10) with a stabilizing Pro-Gly-Pro tail.
2. Therapeutic peptides in gerontology (Frontiers in aging, 2026): Semax has been used clinically in Russia for acute ischemic stroke, cognitive impairment, and attention disorders since the 1980s.
3. Therapeutic Peptides in Orthopaedics (Journal of the American Academy of Orthopaedic Surgeons, 2026): The bulk of Semax literature is Russian-language and has not been independently replicated in large Western trials.
4. 21 CFR 216.23 (FDA 503A Bulks List): Semax does not appear on the FDA's bulk drug substances list for 503A compounding pharmacies.
5. 21 CFR 216.24 (FDA 503B Bulks List): Semax does not appear on the FDA's bulk drug substances list for 503B outsourcing facilities.
6. Semax increases BDNF in rat basal forebrain (Journal of neurochemistry, 2006): Intranasal Semax (50 µg/rat) increased BDNF protein in hippocampus and frontal cortex with no change in striatum.
7. Semax activates neurotrophin transcription after ischemia (Cellular and molecular neurobiology, 2010): Semax upregulates the transcription of BDNF and its receptor TrkB after cerebral ischemia in rodents.
8. Semax activates dopaminergic and serotonergic systems (Neurochemical research, 2005): Semax increases dopamine and serotonin turnover in rodent striatum and hypothalamus.
9. Semax targets μ-opioid receptor gene Oprm1 after spinal cord injury (British journal of pharmacology, 2025): Semax promoted deubiquitination of Oprm1 and improved functional recovery in female mice with spinal cord injury.
10. Synthetic corticotropins and the GABA-receptor system (Chemical biology & drug design, 2023): Semax potentiates GABA_A receptor signaling in certain brain regions.
11. Semax affects gene expression in rat focal ischemia (BMC genomics, 2014): Genome-wide analysis showed Semax (50 µg/kg intranasal) altered hundreds of genes related to immune response, vascular remodeling, and cell survival after rat stroke.
12. ACTH-like peptides compensate gene expression after ischemia (Biomedicines, 2024): Semax partially normalized gene expression disrupted by ischemia one day after experimental stroke in rats.
13. Genes associated with ACTH-like peptides in ischemic brain regions (International journal of molecular sciences, 2025): Semax effects were most pronounced in the penumbra, targeting genes tied to oxidative stress, apoptosis, and immune infiltration.
14. Brain protein expression confirms Semax neuroprotection (International journal of molecular sciences, 2021): Proteomic analysis showed Semax increased heat shock proteins, antioxidant enzymes, and synaptic scaffold proteins after ischemia.
15. Transthyretin in regulatory peptide neuroprotection (Molekuliarnaia genetika, mikrobiologiia i virusologiia, 2016): Semax modulates transthyretin, a transport protein that may regulate amyloid-beta clearance.
16. Efficacy of Semax in ischemic stroke patients (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018): Russian trials reported that Semax (12-18 mg/day intranasal for 5-10 days) improved neurological outcomes when started within 6-12 hours of stroke onset.
17. Effects of Semax on the Default Mode Network (Bulletin of experimental biology and medicine, 2018): A single intranasal dose of Semax (100 µg/kg) altered default mode network connectivity in healthy volunteers on fMRI.
18. Nootropic and analgesic effects of Semax by different routes (Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 2010): Intranasal, subcutaneous, and intraperitoneal Semax all improved spatial memory in rats, with intranasal dosing being most efficient.
19. Therapeutic possibility of Semax for depression (CNS spectrums, 2008): An unblinded case series reported that Semax (3 mg/day intranasal for 14 days) reduced depression scores in patients with major depressive disorder.
20. Semax derivative for Alzheimer's disease model (Acta naturae, 2025): Semax and a metabolite partially reversed memory deficits and reduced oxidative stress in rats injected with Aβ(1-42) peptide.
21. Semax affects copper-induced Abeta aggregation (ACS chemical neuroscience, 2022): Semax interfered with copper-induced amyloid-beta aggregation in artificial membrane models.
22. N-terminus acetylation of Semax affects metal coordination (Journal of inorganic biochemistry, 2016): N-terminal acetylation of Semax enhances its affinity for copper and zinc ions and alters biological properties.
23. Bioactive peptides in neurodegenerative diseases (Neuropeptides, 2025): The literature on bioactive peptides in neurodegeneration is littered with compounds that look promising in animal models but fail in humans.
24. 21 U.S.C. 353a (pharmacy compounding statute): U.S. compounding pharmacies operating under Section 503A must use bulk substances from the FDA's approved list or the USP-NF.
25. 21 CFR 201.128 (meaning of intended uses): FDA can determine intended use of a product based on labeling, marketing, and known use patterns, even if a vendor disclaims human consumption.
26. Functional connectomic approach to Selank and Semax effects (Doklady biological sciences, 2020): Some users report stimulant-like effects (increased alertness, motivation) suggesting dopaminergic activity; others notice no subjective change.